Artiva Biotherapeutics (NASDAQ:ARTV) Releases Earnings Results, Misses Estimates By $0.07 EPS

Artiva Biotherapeutics (NASDAQ:ARTV) issued its earnings results on Friday. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07), FiscalAI reports.

Artiva Biotherapeutics Price Performance

Shares of NASDAQ ARTV opened at $10.89 on Friday. The business’s 50 day moving average is $7.59 and its two-hundred day moving average is $5.35. Artiva Biotherapeutics has a 1-year low of $1.47 and a 1-year high of $14.53. The stock has a market capitalization of $269.20 million, a P/E ratio of -3.08 and a beta of 2.86.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several institutional investors have recently made changes to their positions in the company. Prelude Capital Management LLC purchased a new stake in Artiva Biotherapeutics in the 3rd quarter worth about $41,000. Bank of America Corp DE lifted its stake in Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after purchasing an additional 11,190 shares during the last quarter. OMERS ADMINISTRATION Corp bought a new stake in Artiva Biotherapeutics in the fourth quarter worth about $91,000. Bridgeway Capital Management LLC bought a new stake in Artiva Biotherapeutics in the second quarter worth about $53,000. Finally, Qube Research & Technologies Ltd bought a new stake in Artiva Biotherapeutics in the second quarter worth about $58,000.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ARTV shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. Wall Street Zen upgraded shares of Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Needham & Company LLC reiterated a “buy” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a research report on Monday, May 4th. Finally, HC Wainwright boosted their price objective on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $25.33.

Trending Headlines about Artiva Biotherapeutics

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: Artiva reported positive initial data for AlloNK across multiple autoimmune diseases, including a 71% ACR50 response in refractory rheumatoid arthritis patients, and said the FDA agreed to a single Phase 3 registrational trial design for AlloNK plus rituximab in refractory RA. Article Title
• Positive Sentiment: Management highlighted that the Phase 3 trial could begin in the second half of 2026, with a meaningful market opportunity in heavily pretreated rheumatoid arthritis patients, supporting the long-term bull case. Article Title
• Neutral Sentiment: Artiva also reported first-quarter 2026 results and outlined recent business progress, reinforcing investor focus on the company’s pipeline and upcoming clinical milestones. Article Title
• Neutral Sentiment: The company’s quarterly loss was slightly worse than expected, but the earnings miss was not the main market-moving catalyst compared with the clinical updates and financing news. Article Title
• Negative Sentiment: Artiva priced a $300 million stock and pre-funded warrant offering, which likely pressured the shares because it increases dilution even as it strengthens the balance sheet. Article Title
• Negative Sentiment: Investor enthusiasm for the strong data appeared to be tempered by concern that the financing may offset some of the upside from the trial progress. Article Title

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.